Advertisement
New Zealand markets closed
  • NZX 50

    12,349.47
    -46.80 (-0.38%)
     
  • NZD/USD

    0.5890
    +0.0001 (+0.01%)
     
  • NZD/EUR

    0.5417
    -0.0009 (-0.16%)
     
  • ALL ORDS

    8,153.40
    +59.10 (+0.73%)
     
  • ASX 200

    7,921.30
    +60.10 (+0.76%)
     
  • OIL

    76.44
    -1.84 (-2.35%)
     
  • GOLD

    2,385.70
    +32.20 (+1.37%)
     
  • NASDAQ

    19,023.66
    +193.07 (+1.03%)
     
  • FTSE

    8,285.71
    +99.36 (+1.21%)
     
  • Dow Jones

    40,589.34
    +654.27 (+1.64%)
     
  • DAX

    18,417.55
    +118.83 (+0.65%)
     
  • Hang Seng

    17,021.31
    +16.34 (+0.10%)
     
  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     
  • NZD/JPY

    90.5250
    -0.0680 (-0.08%)
     

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors

Few pharmaceutical giants have performed as well or better than Eli Lilly (NYSE: LLY) in the stock market over the past year. The Indianapolis-based company's secret wasn't its financial results, as they were relatively mild, or even downright disappointing, for much of this period. The market is forward-looking, and with the drugmaker producing several highly promising programs, investors are increasingly excited regarding Eli Lilly's future.